Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Vertex Pharmaceuticals ... AstraZeneca is the only big pharma company to have announced in-house CRISPR/Cas9 research, and earlier this year claimed its programmes were the most advanced in ...

Most investors are happy if a stock doubles within four or five years. Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders should be ecstatic. Its share price has skyrocketed 140% over the last ...

David Paul Morris/Bloomberg via Getty Images Several pharmaceutical stocks ... Bristol-Myers Squibb, and Vertex Pharmaceuticals. The pharma industry has underperformed in 2024 despite several ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...

Former President Donald Trump shared AI-generated images of women wearing "Swifties for Trump" t-shirts to his Truth Social account on Sunday, including a satirical post that claimed Taylor Swift ...

My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai, ...

providing Vertex Pharmaceutical Inc. (NASDAQ:VRTX) with a steady revenue stream and supporting its continued investment in research and development. Vertex Pharmaceutical Inc. (NASDAQ:VRTX)’s ...

This was the stock's second consecutive day of losses.